At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 550 enrolled
Drug / intervention
mRNA-1073 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age
In Brief
A Phase 2 clinical trial evaluating mRNA-1073, mRNA-1010, and 2 other interventions for SARS-CoV-2 and Influenza. Completed, enrolled 550 participants across 14 sites.
Detailed Summary
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2, Influenza
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartMay 2022
First PostedMay 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedMay 17, 2022
Enrollment StartMay 13, 2022
Primary CompletionDec 29, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.1 years ago
Interventions
mRNA-1073biological
Sterile liquid for injection
mRNA-1010biological
Sterile liquid for injection
mRNA-1273biological
Sterile liquid for injection
Placebobiological
0.9% sodium chloride (normal saline) injection